文献速递胸部肿瘤头颈与中枢神经肿瘤

奥希替尼对T790M阳性晚期NSCLC中枢神经系统转移的疗效:两项II期试验汇总分析

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.
PubMed 文献 · Ann Oncol · 2018-01-01

该分析汇总AURA extension和AURA2两项II期试验中411例T790M阳性晚期NSCLC患者,其中50例有可测量CNS病灶者纳入CNS可评估集。结果显示经BICR评估的CNS客观缓解率为54%,疾病控制率为92%,CNS缓解持续时间9个月时75%的患者仍维持缓解,安全性与此前报道一致。

要点

  • 奥希替尼80mg每日一次在T790M阳性晚期NSCLC的CNS转移中显示临床意义疗效。
  • CNS可评估集中确认的CNS ORR为54%,DCR为92%。
  • 无论既往是否接受脑部放疗,均观察到CNS缓解。

核心结论

  • 奥希替尼对CNS转移显示临床意义疗效,具有高DCR和令人鼓舞的ORR,安全性与此前报道一致。

研究设计与样本

  • 汇总AURA extension(NCT01802632)和AURA2(NCT02094261)两项II期研究的预设CNS亚组分析。
  • 411例T790M阳性晚期NSCLC患者接受奥希替尼80mg每日一次,均为既往EGFR-TKI治疗后进展者。
  • 基线脑扫描经盲法独立中心神经影像学评审(BICR)确认至少1个可测量CNS病灶的50例患者纳入CNS可评估集(cEFR)。

主要发现

  • 基线脑扫描显示128例患者存在CNS转移,其中50例纳入cEFR。
  • 确认的CNS ORR为54%(27/50;95%CI 39-68),CNS DCR为92%(46/50;95%CI 81-98)。
  • 无论既往是否接受脑部放疗,均观察到CNS缓解。
  • CNS缓解持续时间中位值未达到(范围1-15个月),9个月时75%(95%CI 53-88)的患者估计仍维持缓解。
  • CNS PFS中位随访11个月,中位CNS PFS未达到(95%CI 7-不可计算),cEFR安全性特征与总体人群一致。

关键数值与推荐

  • CNS ORR为54%(27/50;95%CI 39-68),CNS DCR为92%(46/50;95%CI 81-98)。
  • 9个月时75%(95%CI 53-88)的患者估计仍维持CNS缓解。
  • 中位CNS PFS未达到(95%CI 7-不可计算),中位随访11个月。

临床怎么用

  • 对于T790M阳性晚期NSCLC伴稳定无症状CNS转移的患者,奥希替尼80mg每日一次可作为治疗选择。
  • 既往接受过脑部放疗的患者仍可观察到CNS缓解,支持奥希替尼在CNS转移中的使用。

局限性

  • CNS可评估集样本量较小(50例),CNS缓解持续时间数据成熟度低(22%)。
  • 为两项II期研究的汇总亚组分析,非头对头比较设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Central nervous system (CNS) metastases are common in patients with non-small-cell lung cancer (NSCLC). Osimertinib has shown systemic efficacy in patients with CNS metastases, and early clinical evidence shows efficacy in the CNS. To evaluate osimertinib activity further, we present a pre-specified subgroup analysis of CNS response using pooled data from two phase II studies: AURA extension (NCT01802632) and AURA2 (NCT02094261). PATIENTS AND METHODS: Patients with T790M-positive advanced NSCLC, who had progressed following prior epidermal growth factor receptor-tyrosine kinase inhibitor treatment, received osimertinib 80 mg od (n = 411). Patients with stable, asymptomatic CNS metastases were eligible for enrolment; prior CNS treatment was allowed. Patients with ≥1 measurable CNS lesion (per RECIST 1.1) on baseline brain scan by blinded independent central neuroradiology review (BICR) were included in the evaluable for CNS response set (cEFR). The primary outcome for this CNS analysis was CNS objective response rate (ORR) by BICR; secondary outcomes included CNS duration of response, disease control rate (DCR) and progression-free survival (PFS). RESULTS: Of 128 patients with CNS metastases on baseline brain scans, 50 were included in the cEFR. Confirmed CNS ORR and DCR were 54% [27/50; 95% confidence interval (CI) 39-68] and 92% (46/50; 95% CI 81-98), respectively. CNS response was observed regardless of prior radiotherapy to the brain. Median CNS duration of response (22% maturity) was not reached (range, 1-15 months); at 9 months, 75% (95% CI 53-88) of patients were estimated to remain in response. Median follow-up for CNS PFS was 11 months; median CNS PFS was not reached (95% CI, 7, not calculable). The safety profile observed in the cEFR was consistent with the overall patient population. CONCLUSIONS: Osimertinib demonstrated clinically meaningful efficacy against CNS metastases, with a high DCR, encouraging ORR, and safety profile consistent with that reported previously. CLINICALTRIALS.GOV NUMBER: NCT01802632; NCT02094261.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Goss G, Tsai CM, Shepherd FA, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018. PMID: 29293889. doi:10.1093/annonc/mdx820

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。